drugset

drugset / Trial / NCT06566586

A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma

NCT06566586 ↗

Phase 2 Recruiting 80 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of TQB3702 tablets combined with immunochemotherapy for the treatment of B-cell lymphoma

Timeline

Start: 2024-11-06
Primary completion: 2026-03
Completion: 2027-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TQB3702	Unknown	200 mg	—

Indications